



Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

Tetsuhiro Tanaka¹ · Masaomi Nangaku¹ · Enyu Imai² · Yoshiharu Tsubakihara³ · Masatoshi Kamai⁴ · Michihito Wada⁵ · Shinji Asada⁵ · Tadao Akizawa⁶

Published online: 23 January 2019
© Japanese Society of Nephrology 2019

Correction to: Clinical and Experimental Nephrology
<https://doi.org/10.1007/s10157-018-1632-9>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

In the original publication of the article, two sentences in the “Results” section were published incorrectly. The corrected texts are provided below:

1. In the first paragraph of the section “Effectiveness”, 10th line should read as “The administered dose of darbepoetin (mean \pm SD, μ g) in the effectiveness analysis”.
2. In the fourth paragraph of the section “Effectiveness”, 1st line should read as “Female patients or those with advanced age...baseline systolic blood pressure \geq 130 mmHg”.

The original article can be found online at <https://doi.org/10.1007/s10157-018-1632-9>.

✉ Shinji Asada
shinji.asada@kyowa-kirin.co.jp

¹ Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan

² Internal Medicine of Nakayamadera Imai Clinic, Takarazuka, Hyogo, Japan

³ Graduate School of Health Care Sciences, Jikei Institute, Yodogawa-ku, Osaka, Japan

⁴ Pharmacovigilance Department, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan

⁵ Medical Affairs Department, Kyowa Hakko Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan

⁶ Showa University, Shinagawa-ku, Tokyo, Japan